A Study of GFH018 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is the first in human study of GFH018 comprised of a dose escalation part and a dose
expansion part in subjects with advanced solid tumors after single/multiple administration.
The study is designed to explore the safety/tolerability, pharmacokinetics, and MTD of GFH018
and to define a RP2D of GFH018.